<DOC>
	<DOCNO>NCT00002949</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy vinorelbine paclitaxel plus radiation therapy treat patient advanced cancer arise pelvis .</brief_summary>
	<brief_title>Vinorelbine Paclitaxel Plus Radiation Therapy Treating Patients With Advanced Cancer Arising Pelvis</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxic effect vinorelbine give weekly schedule combine standard whole pelvic radiation therapy . II . Determine Maximum Tolerated Dose ( MTD ) vinorelbine give weekly schedule combine standard whole pelvic radiation therapy . III . Access toxic effect paclitaxel give weekly combination regimen determine MTD vinorelbine . IV . Determine MTD paclitaxel give weekly combination regimen determine MTD vinorelbine . OUTLINE : Part I : Vinorelbine IV bolus administer 8-10 minute day 1 prior radiation therapy . Whole pelvic radiation treatment give day 1-5 follow 2 day rest . The treatment volume encompasses suspect pelvic disease minimum 1 cm margin . Cycles repeat weekly . Dose vinorelbine escalate cohort least 3 patient maximum tolerate dose ( MTD ) determine . Part II : Paclitaxel infuse 1 hour immediately follow vinorelbine MTD , determine part I . Dose paclitaxel escalate cohort least 3 patient MTD determine . At least 6 patient treat MTD part I II study . Patients follow late chronic toxicity . PROJECTED ACCRUAL : Projected accrual 12 patient per year approximately 3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced carcinoma uterine cervix , vagina , bladder pelvic malignancy whole pelvic radiation therapy plan Metastatic disease permit PATIENT CHARACTERISTICS : Age : Over 18 Performance status : CALGB 02 Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin within normal limit Renal : Creatinine great 2.5 mg/dL Cardiovascular : No unstable angina myocardial infarction previous 6 month Other : Not pregnant No significant concomitant illness , uncontrolled infection , cirrhosis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior whole pelvic radiation therapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage II cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IV cervical cancer</keyword>
	<keyword>stage II vaginal cancer</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
</DOC>